Update on vaccines for melanoma patients

Vincenzo Russo, Cristina Maccalli, Lorenzo Pilla, Santo Raffaele Mercuri, Elena Orsenigo, Sylvain Mukenge, Marco Bregni, Giorgio Parmiani

Research output: Contribution to journalReview article


Vaccination against melanoma has a long history but only recently has this therapeutic approach found a reliable scientific rationale. This review summarizes and updates the knowledge on the role of the main players in the vaccination strategy against metastatic melanoma, that is, the melanoma-associated antigens recognized by T and natural killer T lymphocytes, the conditions for the immune response to develop and the mechanisms that interfere with it. A commented list of the major vaccination trials whose results have been recently, published or are ongoing is also presented. Reasons for failure and potential success are underlined to offer a balanced view of this scientifically exciting but still clinically unrewarding field of investigation.

Original languageEnglish
Pages (from-to)195-207
Number of pages13
JournalExpert Review of Dermatology
Issue number2
Publication statusPublished - 1 Apr 2008
Externally publishedYes



  • Melanoma
  • Melanoma vaccines
  • Melanoma-associated antigens
  • NKG2D
  • T lymphocytes
  • T-cell responses

ASJC Scopus subject areas

  • Dermatology

Cite this

Russo, V., Maccalli, C., Pilla, L., Mercuri, S. R., Orsenigo, E., Mukenge, S., Bregni, M., & Parmiani, G. (2008). Update on vaccines for melanoma patients. Expert Review of Dermatology, 3(2), 195-207. https://doi.org/10.1586/17469872.3.2.195